1. Home
  2. IVP vs SHPH Comparison

IVP vs SHPH Comparison

Compare IVP & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inspire Veterinary Partners Inc.

IVP

Inspire Veterinary Partners Inc.

HOLD

Current Price

$0.06

Market Cap

2.9M

Sector

Miscellaneous

ML Signal

HOLD

Logo Shuttle Pharmaceuticals Holdings Inc.

SHPH

Shuttle Pharmaceuticals Holdings Inc.

HOLD

Current Price

$1.87

Market Cap

3.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IVP
SHPH
Founded
2020
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
3.2M
IPO Year
2023
2022

Fundamental Metrics

Financial Performance
Metric
IVP
SHPH
Price
$0.06
$1.87
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
75.5M
313.5K
Earning Date
11-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,560,011.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.06
$1.26
52 Week High
$5.96
$25.25

Technical Indicators

Market Signals
Indicator
IVP
SHPH
Relative Strength Index (RSI) 18.98 44.40
Support Level $0.07 $1.64
Resistance Level $0.11 $1.79
Average True Range (ATR) 0.03 0.23
MACD 0.01 0.09
Stochastic Oscillator 1.59 71.68

Price Performance

Historical Comparison
IVP
SHPH

About IVP Inspire Veterinary Partners Inc.

Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.

About SHPH Shuttle Pharmaceuticals Holdings Inc.

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.

Share on Social Networks: